Pregled bibliografske jedinice broj: 1238015
Risankizumab: IL-23 inhibitor u liječenju psorijaze
Risankizumab: IL-23 inhibitor u liječenju psorijaze // Medix (Zagreb), (2020), 143; 64-69 (domaća recenzija, članak, stručni)
CROSBI ID: 1238015 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Risankizumab: IL-23 inhibitor u liječenju psorijaze
(Risankizumab: IL-23 inhibitor in the treatment of
psoriasis)
Autori
Čarija, Antoanela
Izvornik
Medix (Zagreb) (1331-3002)
(2020), 143;
64-69
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
psorijaza ; risankizumab, sigurnost ; učinkovitost ; inhibitor IL-23
(psoriasis ; risankizumab, safety ; effectiveness ; IL-23 inhibitor)
Sažetak
The IL-23 / Th17 axis is a central development in the immunopathogenesis of psoriasis. Risankizumab (Skyrizi) is indicated for the treatment of moderate to severe plaque psoriasis in adults. Risankizumab is a humanized high-affinity IgG1 monoclonal antibody for the p19 subunit of IL-23, thus preventing IL-23 from binding to the receptor over an extended period of time. The success of IL-23 blockade in the treatment of psoriasis is also evident in the high clinical response rates of PASI 90 and PASI 100. These outcomes were part of clinical trials with risankizumab (UltIMMa-1, UltIMMa-2, IMMhance and IMMvent), which demonstrated superior efficacy over placebo, ustekinumab, adalimumab, as well as in the most recent IMMerge study over secukinumab. Risankizumab is a drug of very good safety and tolerability and in these studies without significant differences in the occurrence of serious side effects compared to placebo, ustekinumab, adalimumab and secukinumab.
Izvorni jezik
Hrvatski
Znanstvena područja
Kliničke medicinske znanosti
